Nuclear Medicine Unit, Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy.
Nuclear Medicine Unit, Azienda Ospedaliera "Pugliese-Ciaccio", 88100 Catanzaro, Italy.
Curr Oncol. 2024 Nov 3;31(11):6879-6890. doi: 10.3390/curroncol31110508.
To meta-analyze the utility of transarterial radioembolization (TARE) in patients with liver metastatic breast cancer (BC), based on the objective response rate (ORR) and disease control rate (DCR).
A literature search was performed retrieving studies with (1) at least 10 patients with liver metastatic BC treated with TARE and (2) adequate information to derive ORR and DCR. The ORR is the ratio between patients with liver lesions showing complete response (CR) or partial response (PR) over the total number of patients treated with TARE; the DCR is the ratio between patients with CR, PR, or stable disease (SD) over the total number of patients treated with TARE.
Eighteen studies (650 patients) were eligible; the ORR of TARE resulted 50.71% (95% C.I.: 40.04-61.36) and the DCR resulted 88.37% (95% C.I.: 81.89-93.57). Taking into account resin spheres (395 patients), the ORR was 60.35% (95% C.I.: 46.55-73.36) and the DCR was 92.73% (95% C.I.: 87.17-96.80%). Considering glass spheres (144 patients), the ORR was 32.38% (95% C.I.: 18.43-48.16) and the DCR was 82.69% (95% C.I.: 59.29-97.26).
This meta-analysis favors the use of TARE in patients with liver metastatic BC either with resin or glass spheres.
基于客观缓解率(ORR)和疾病控制率(DCR),对经动脉放射性栓塞术(TARE)治疗肝转移乳腺癌(BC)患者的疗效进行荟萃分析。
检索至少有 10 例肝转移 BC 患者接受 TARE 治疗且有足够信息得出 ORR 和 DCR 的研究。ORR 为肝病变完全缓解(CR)或部分缓解(PR)患者与接受 TARE 治疗的患者总数之比;DCR 为 CR、PR 或疾病稳定(SD)患者与接受 TARE 治疗的患者总数之比。
18 项研究(650 例患者)符合条件;TARE 的 ORR 为 50.71%(95%置信区间:40.04-61.36),DCR 为 88.37%(95%置信区间:81.89-93.57)。考虑到树脂球(395 例),ORR 为 60.35%(95%置信区间:46.55-73.36),DCR 为 92.73%(95%置信区间:87.17-96.80)。考虑玻璃球(144 例),ORR 为 32.38%(95%置信区间:18.43-48.16),DCR 为 82.69%(95%置信区间:59.29-97.26)。
本荟萃分析支持使用 TARE 治疗肝转移 BC 患者,无论使用树脂球还是玻璃球。